Neel R. Gandhi, MD

Associate Professor

Department of Epidemiology, Department of Global Health and Infectious Diseases (Jointly appointed)

Phone: 404-727-2317


Research Interests

Neel R. Gandhi, M.D is Associate Professor in the Departments of Epidemiology, Global Health and Infectious Diseases at Emory University’s Rollins School of Public Health and Emory School of Medicine.  Dr. Gandhi received his Bachelor of Arts degree in Chemistry from Williams College in 1994, and his M.D. degree in 1999 from Brown University School of Medicine.  After completing residency in Internal Medicine, Dr. Gandhi received Epidemiology training in the Robert Wood Johnson Clinical Scholars Program at Yale University, and Infectious Disease training at Emory School of Medicine.  He served on the faculty at Albert Einstein College of Medicine from 2006 to 2012.  In July 2012, Dr. Gandhi returned to Emory to join the faculty at the Schools of Public Health and Medicine.

Dr. Gandhi has been engaged in clinical research in Tuberculosis and HIV co-infection since 1998.  Since 2002, Dr Gandhi has led a research team focused on epidemiology and clinical research studies to improve care for TB patients co-infected with HIV.  In 2006, Dr Gandhi was the lead author on a study describing high rates of mortality in patients with extensively drug-resistant tuberculosis (XDR TB) and HIV co-infection in the rural town of Tugela Ferry.  This study has been credited for uncovering a rapidly expanding multidrug-resistant (MDR) TB and XDR TB epidemic in South Africa. 

Since the discovery of the drug-resistant TB epidemic in South Africa, Dr. Gandhi’s research group has focused on characterizing the epidemiology, and improving diagnosis and treatment of MDR and XDR TB.  His research group has demonstrated that transmission of drug-resistant TB strains, in healthcare and community settings, is major factor in driving the rapid expansion of the epidemic.  They have also shown that MDR TB treatment outcomes, among HIV co-infected individuals, can be improved to rates similar to those without HIV, if antiretroviral therapy is given concurrently. His research group is now investigating the risk of developing resistance to bedaquiline, as well as drug-drug interactions with antiretroviral therapy, among pre-XDR and XDR TB patients.

In addition to NIH funding for the South African studies, Dr. Gandhi is also collaborating with colleagues at Emory and in TB Research Unit (TBRU) ASTRa, to understand adaptive and innate immune responses and their relationship to outcomes following Mtb exposure, including active TB disease, prolonged latent TB infection, and clearance or resistance to infection. Dr. Gandhi’s group has collaborated with the US CDC and Kenya Medical Research Institute to establish a study site in Kisumu, Kenya, and with the DeKalb County Board of Health for a study site in Atlanta for these studies.

Dr. Gandhi is also committed to training the next generation of TB, HIV and Global Health researchers through teaching and mentoring activities. He is the recipient of an NIH K24 mentorship grant, as well as mentoring individual early career development K awards, and serving as training faculty on several T32 and D43 grants.